Schema-Root.org logo

 

  cross-referenced news and research resources about

 lymphomas

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. January 24, 2018

-
In the study, the researchers administered the engineered T-cells to eight patients with Epstein Barr-positive Hodgkin's lymphoma. Doses ranged from two to 12, and the amount in each ranged from 2 x 107 to 1.5 x 108cells/m2. The results were promising, with the treatment working to keep the illness at ...
Professor Owen O'Connnor of Columbia University Medical Center in New York, and colleagues, conducted a multicenter trial of brentuximab vedotin plus bendamustine for treating relapsed or refractory Hodgkin's lymphoma. The results were published December 21, 2017 in The Lancet Oncology.

Adcetris (brentuximab vedotin) in combination with chemotherapy is a valuable treatment option for patients with previously untreated advanced Hodgkin's lymphoma, researchers said after revealing data from a Phase 3 clinical trial. Adcetris, an anti-CD30 antibody-drug conjugate, is currently approved for ...
Celgene will buy Juno Therapeutics for $9 billion in a deal that gives Celgene access to an experimental gene therapy for treating people with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. The acquisition, announced Jan. 22, significantly strengthens Celgene's lymphoma portfolio.
Now there are 3 very common types of low-grade lymphomas: SLL (small lymphocytic lymphoma), marginal zone lymphoma, and follicular lymphoma. With follicular lymphomas, the way we often differentiate between the 2 is how they look under the microscope as well as through immunohistochemistry.

ATLANTA -- Combination therapy with ibrutinib and nivolumab appears safe and effective for several subtypes of relapsed, refractory non-Hodgkin lymphoma, with clinical response rates in Richter's transformation that "exceeded expectation," according to findings presented at the ASH Annual Meeting ...
While most patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard R-CHOP, 30% to 40% of cases report chemotherapy resistance. In an attempt to counter chemo-resistant DLBCL, Peter Martin, MD, along with several other colleagues at Weil Cornell Medicine, set out to test ...
Treatment of previously untreated follicular lymphoma with atezolizumab checkpoint-inhibition immunotherapy combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study ...
A new method for growing the T-cells used in lymphoma immunotherapies may some day lead to treatments that are faster and do a better job of honing in on a specific target. A research team at two Harvard institutions developed a way to mimic signals from the antigen-presenting cells (APCs) that instruct ...
Panelists: Alexey V. Danilov, MD, PhD, Oregon Health & science University; Andre Goy, MD, Hackensack University Medical Center; John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medical Center; John M. Pagel, MD, PhD, DSc, Swedish Medical Center Seattle and Issaquah; Stephen J.
Long-term follow-up results of the FOLL05 trial confirm the efficacy of immunochemotherapy regimens for patients with previously untreated advanced-stage follicular lymphoma (FL), according to findings of a post-hoc analysis recently published in the Journal of Clinical Oncology covering a median 7 ...
ATLANTA -- A combination of brentuximab vedotin with nivolumab appeared tolerable and safe among patients with relapsed or refractory Hodgkin lymphoma, according to results from a phase 1/phase 2 clinical trial presented at the ASH Annual Meeting and Exposition. An unmet clinical need remains for ...
Andrew M. Evens, DO, MSc, FACP, has been named associate director for clinical services at Rutgers cancer Institute. In this role, he will oversee and facilitate integration of all multidisciplinary clinical programs across the institute, including those focused on palliative care, navigational support and ...
While there are no means of preventing or screening for most blood cancers, recent breakthroughs for lymphoma treatment are improving quality of life and survival. lymphomas are cancers of the lymphocytes, a type of white blood cell of the lymphatic system which play a key role in the body's immune system. The two ...
Stanford linebacker Ryan Beecher announced on Friday that he was diagnosed with non-Hodgkin lymphoma last month. "In December, I was diagnosed with non-Hodgkin lymphoma," Beecher wrote on twitter. "I am receiving treatments while attending classes at Stanford. I look forward to making a full and ...

Over 4,000 patients enrolled within nine months of their lymphoma diagnosis at the Mayo Clinic between 2002 and 2012. At enrollment, patients completed questionnaires about their usual level of mild, moderate and strenuous physical activity before diagnosis. The researchers continued to contact the ...
Initial treatment with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) offers a better chance of durable disease control for patients with advanced follicular lymphoma (FL) than R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) or rituximab plus ...
Constant attack on T cell lymphomas. Gabriel K. Griffin. Department of Pathology, Brigham and women's hospital ... A proof-of-principle study generates CAR-T cells against T cell lymphoma by selectively targeting the T cell receptor β-chain constant region 1. copyright © 2017, American Association for the Advancement of ...
Leo I. Gordon, MD, a professor of medicine at Feinberg school of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma. Data suggests that the immune system and the use of checkpoint inhibitors may play an important role in Hodgkin lymphoma, says Gordon. These novel ...
"It's very exciting to see that this drug combination has an impact on survival of mice with lymphoma, as improvements in treatment are urgently needed. The next stage will be to see if what we've discovered can be replicated in patients." Professor Karen Vousden, cancer Research UK's chief scientist, said: ...
scientists at The Institute of Cancer Research, London, identified six new genetic changes that increase the risk of developing Hodgkin lymphoma -- one of the most common cancers in young adults. Many of the DNA changes seemed to affect the function of the immune system, and three had previously ...
Takeda pharmaceuticals Korea announced Tuesday that the European Medicines Agency (EMA) Committee for Medicinal Products for Human ...
The FDA granted priority review to mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who underwent at least one ...
Janssen's Imbruvica (ibrutinib) - an approved therapy for relapsed or refractory mantle cell lymphoma - continues to show promising survival ...
Adult patients with inflammatory bowel disease (IBD) who receive thiopurine monotherapy or anti-tumor necrosis factor (TNF) monotherapy ...
Immunohistochemical analysis of diffuse large B cell lymphomas ... a new molecule that demonstrates its ability to inhibit lymphoma growth.
Since 2006, first-line therapy for indolent B-cell lymphoma has ... However, despite initial response to first-line therapy, indolent lymphomas are ...
Takeda has announced that its cancer therapy Adcetris has been recommended for European approval as a treatment for another form of ...
Patients with lymphoma who suffer from moderate to severe anemia may have better outcomes after 3 months receiving the same supportive ...
A kindergarten student named Emma is currently battling Burkitt's lymphoma. Her school, Mill Village Elementary and the surrounding ...
Nonetheless, the results have convinced Takeda to suggest Adcetris as a new frontline therapy in Hodgkin's lymphoma. Seattle genetics ...
EB) said Friday that the U.S. Food and Drug Administration approved Gazyva for previously untreated advanced follicular lymphoma, a form of ...
The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment ...
In this May 2016 file photo provided by Kite PhaRMA, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., ...
Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start ...
lymphomas arise when immune cells called lymphocytes become ... the once fatal diagnosis of B-cell lymphoma into a curable condition.
lymphomas arise when immune cells called lymphocytes become ... the once fatal diagnosis of B-cell lymphoma into a curable condition.
The FDA has approved brentuximab vedotin (Adcetris, Seattle genetics, Inc.) for the treatment of adults with primary cutaneous anaplastic large ...
Certain prostate cancers and lymphomas have a major genetic weakness that doctors can exploit to help save patients' lives, researchers at ...
Nivolumab may provide long-term clinical benefits for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after ...
FDA Approves Adcetris for lymphoma Subset ... of care in CD30-expressing lymphomas and this approval represents our fourth FDA-approved ...
"Patients initially treated with R-CVP had a higher risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher ...
... approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL.
Significant shifts in the management of lymphoma continue thanks to new ... lymphomas are currently treated with rituximab (Rituxan), ...
The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma. All patients had not received prior ...
... marker of classical Hodgkin lymphoma. ADCETRIS is being evaluated globally as the foundation of care for CD30-expressing lymphomas in ...
Patients with diffuse large B-cell lymphoma and follicular lymphoma at ... as aggressive lymphomas, patients with follicular lymphoma/DLBCL ...
An international team of scientists has pinpointed the genetic drivers of diffuse large B-cell lymphoma--the most common type of blood ...


 

news and opinion


 


 


 


 


schema-root.org

   human
    diseases
     cancer
       lymphoma
         hodgkin's
         non‑hodgkin's

cancers:
       brain
       breast
       cervix
       colon
       lung
       lymphoma
       oral
       radiogenic
       skin